From tablets and capsules to topical treatments... HanAll Biopharma completes its hair-loss lineup

[Financial News] A minoxidil hair-loss treatment has been launched with a spray-style dispensing container that lets users dispense and spray only as much as they need. HanAll Biopharma said on the 8th that it had launched Pangro Solution 5%, a 200 mL over-the-counter medicine.
Pangro Solution 5% is a topical product applied directly to the scalp, containing minoxidil, which is used to treat male pattern hair loss (androgenetic alopecia). To make it more convenient, the product comes with a portable, easy-to-use dispensing container in addition to the large-capacity main bottle.
With this launch, HanAll Biopharma now offers topical Pangro Solution 5%, adding to its finasteride product Hairgrow Tablets; its dutasteride products Adamo Tablets and Adamo Soft Capsules; and its hair-loss adjunct treatment Pangro Capsules. The company said the expanded lineup covers key hair-loss treatment ingredients and dosage forms, from oral medications to topical products, giving consumers more options for managing hair loss.
HanAll Biopharma has steadily expanded its capabilities in this area since selecting hair-loss treatment as one of its key business areas in 2022. That same year, it established a dedicated production line for hair-loss treatments at its Daejeon plant and introduced an automated system covering the entire process and an enclosed manufacturing process, boosting productivity and quality-control capabilities.
The company has also seen results. Monthly sales of its flagship product, Hairgrow Tablets (active ingredient: finasteride), exceeded 2.5 million tablets in September 2025. Pangro, an adjunct treatment for hair loss, won the grand prize in the oral hair-loss treatment category at the 2024 Korea First Brand Awards, whose winners are selected directly by consumers.
The company plans to continue expanding its share of the hair-loss treatment market, building on a product lineup that includes both oral and topical medicines.
HanAll Biopharma CEO Park Su-jin said, “We have steadily built the foundation for our hair-loss treatment business on a dedicated production line for hair-loss treatments and a diverse product portfolio. With this new product launch, we will further solidify our position as a pharmaceutical company specializing in hair-loss treatments.”
 
[email protected] Jeong Myeong-jin, reporter